A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 3 STUDY OF THE SAFETY AND EFFICACY OF OMS721 IN PATIENTS WITH IMMUNOGLOBULIN A (IGA) NEPHROPATHY (ARTEMIS-IGAN)
- Registry ID
- OMS721-IGA-001
- Source registry
- HEALTH_CANADA
- Status
- Ongoing
- Phase
- PHASE3
- Study type
- INTERVENTIONAL
- Sponsor
- OMEROS CORPORATION
- Start date
- 2020-01-17
- Last update
- 2018-05-18
Conditions
- IMMUNOGLOBULIN A NEPHROPATHY
Related clinical trials
- A PHASE 2B, MULTICENTER, OPEN-LABEL, SINGLE-ARM TRIAL TO EVALUATE THE IMPACT OF SIBEPRENLIMAB ON KIDNEY HISTOPATHOLOGY THROUGH REPEAT KIDNEY BIOPSIES IN ADOLESCENTS AND ADULTS WITH IMMUNOGLOBULIN A NEPHROPATHY
- A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF POVETACICEPT
IN ADULTS WITH IMMUNOGLOBULIN A NEPHROPATHY (RAINIER)
- A PHASE 2/3, MULTICENTER, OPEN LABEL TRIAL TO EVALUATE THE LONG TERM SAFETY, TOLERABILITY, AND EFFICACY OF SIBEPRENLIMAB ADMINISTERED SUBCUTANEOUSLY IN SUBJECTS WITH IMMUNOGLOBULIN A NEPHROPATHY
- A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTIPLE DOSE STUDY TO EVALUATE THE EFFICACY AND SAFETY OF VIS649 IN PARTICIPANTS WITH IMMUNOGLOBULIN A (IGA) NEPHROPATHY.
View on source registry